Marc Lajoie, PhD

Marc Lajoie, PhD is co-founder and CEO of Outpace Bio, which uses protein design to transform cell therapies into cures. Prior to Outpace, Dr Lajoie co-founded Lyell, where he led protein engineering and technology development to overcome the mechanisms driving T cell dysfunction. Dr Lajoie completed his postdoctoral studies in David Baker’s lab at the University of Washington, where he helped pioneer the ability to design proteins with moving parts, making it possible to create fundamentally new biological functions. He completed his PhD in George Church’s lab at Harvard University, where he created the first genomically recoded organism with a reassigned genetic code and co-founded GRO Biosciences. Dr Lajoie was named 30 under 30 in science by Forbes Magazine in 2012, 35 Innovators Under 35 by MIT Tech Review in 2019, and Endpoints 20 under 40 in biopharma in 2021. He has authored more than thirty scientific publications and is an inventor on nineteen published patent applications.